Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic review
Biotech
Tempest strikes all-stock deal for Factor’s CAR-T pipeline, CEO
After seeking strategic alternatives, Tempest is inking an all-stock transaction for four of Factor's CAR-T candidates.
Gabrielle Masson
Nov 19, 2025 12:22pm
Charles River lays off 70 staffers as strategic shift begins
Nov 14, 2025 4:40pm
Metagenomi sheds 25% of workforce, including CEO
Nov 12, 2025 6:30am
Neuphoria, reeling from ph. 3 fail, mulls buyout from investor
Nov 11, 2025 8:40am
Charles River to cut costs, shift direction as revenue slides
Nov 5, 2025 12:54pm
Neuphoria nixes social anxiety program after phase 3 flop
Oct 21, 2025 10:44am
